Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

14 mai 2026 mis à jour par: Thea Knowles, Michigan State University

Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

Aperçu de l'étude

Description détaillée

Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication. This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue. Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD. Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes. The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes. The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies. Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD. In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style. Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech. Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1. These acoustic enhancements will serve to simulate potential technological improvements to amplification devices. Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort. Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal. The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone. Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development. Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself. Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population. This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD. It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech. It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Thea Knowles, PhD
  • Numéro de téléphone: 517-353-6401
  • E-mail: thea@msu.edu

Lieux d'étude

    • Michigan
      • East Lansing, Michigan, États-Unis, 48823
        • Recrutement
        • Michigan State University
        • Contact:
          • Thea Knowles, PhD
          • Numéro de téléphone: 517-353-6401
          • E-mail: thea@msu.edu
        • Chercheur principal:
          • Thea Knowles, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Dominant speakers of North American English
  • Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
  • Present with changes in their speech/voice

Exclusion Criteria:

  • History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
  • Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Speech Study
Single arm study: All speech conditions are administered.
Behavioral speech strategies + speech amplification

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Speech intensity
Délai: Day 1
Decibel sound pressure level (dB SPL) measured from speech audio recordings
Day 1
Voice quality
Délai: Day 1
Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings
Day 1
Articulation
Délai: Day 1
Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.
Day 1

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Speech intelligibility
Délai: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
% words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed). Listener participants transcribe speech recorded by speaker participants.
From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
Perceived Listener Effort
Délai: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
% along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech"). Listener participants will rate speech recorded by speaker participants.
From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mars 2024

Achèvement primaire (Estimé)

31 décembre 2027

Achèvement de l'étude (Estimé)

31 mai 2028

Dates d'inscription aux études

Première soumission

5 mai 2026

Première soumission répondant aux critères de contrôle qualité

14 mai 2026

Première publication (Réel)

20 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner